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Detection of serine 473 phosphorylated Akt in acute myeloid
leukaemia blasts by flow cytometry
Acute myeloid leukaemia (AML) is a disease characterized by
the accumulation of immature myeloid cells in the bone
marrow and the suppression of normal haematopoiesis.
Leukaemic blast cells display a myriad of genetic abnormalities,
including alterations of growth factor receptors, such as Flt3,
and activation of signal transduction pathways (Rowley, 1999;
Tse et al, 2000; Jordan, 2002; Lee & McCubrey, 2002). These
findings have suggested a model whereby transcription factor
fusion proteins co-operate with altered survival signalling to
generate a transformed phenotype (Kelly et al, 2002).
Akt or protein kinase B, a serine/threonine protein kinase,
has emerged as a crucial regulator of widely divergent cellular
processes, including apoptosis, proliferation and differenti-
ation (Brazil & Hemmings, 2001). Akt activation is strictly
dependent on phosphorylation of Thr 308 and Ser 473
residues. These phosphorylative events occur in response to
diverse stimuli, including hormones, growth factors and
extracellular matrix components (Chang et al, 2003; Hanada
et al, 2004). Phosphorylation of Thr 308 is dependent on the
lipid products of phosphoinositide 3-kinase, whereas the
mechanism of Ser 473 phosphorylation is less clear (Brazil &
Hemmings, 2001; Cantrell, 2001).
Evidence suggests that constitutive activation (phosphory-
lation) of Akt is frequently observed in various types of
neoplasia (Testa & Bellacosa, 2001; Nicholson & Anderson,
2002). The level of Akt expression and kinase activity are often
associated with the degree of differentiation, hormone
dependency and aggressive behaviour of cancer cells and/or
with a less favourable prognosis. For these reasons, Akt is
currently seen as a major target for the development of novel
anticancer therapeutic treatments (Hill & Hemmings, 2002).
Recently, it has been demonstrated that Akt is activated in
AML blasts (Min et al, 2003; Xu et al, 2003) and Akt
phosphorylation has been proposed as a new tool for
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Università di Bologna, Bologna, and 4Istituto per i
Trapianti d’Organo e l’Immunocitologia del
C.N.R., Sezione di Bologna c/o I.O.R., Bologna,
Italy
Received 4 June 2004; accepted for publication 2
July 2004
Correspondence: A. M. Martelli, Dipartimento
di Scienze Anatomiche Umane e Fisiopatologia
dell’Apparato Locomotore, Università di
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Summary
The phosphoinositide 3-kinase/Akt signalling pathway is a recently
recognized important parameter in the prognosis and the response to
treatment of acute myeloid leukaemia (AML). Akt kinase is activated by
phosphorylation on Thr 308 and Ser 473. Active Akt promotes cell growth
and survival to apoptotic insults. Thus, it seems important to evaluate Akt
phosphorylation in AML blasts. This work aimed to establish whether it was
possible to detect Akt phosphorylation on Ser 473 of AML blasts by means of
flow cytometry. High levels of Akt activity and phosphorylation were
detected in 13 of 15 cases of AML. Flow cytometric analysis revealed similar
patterns of Ser 473 expression as was observed with Akt kinase activity and
Western blot analysis of Thr 308 and Ser 473 phosphorylation. Double
immunostaining enabled the simultaneous flow cytometric detection of an
AML-associated antigen (CD33) and Ser 473 phosphorylated Akt in
leukaemic blast populations. Our results indicate that flow cytometry
enabled the rapid and quantitative assessment of Ser 473 phosphorylated Akt
of AML blasts that, when used in combination with cell surface staining, can
provide more accurate phenotyping of AML blasts.
Keywords: acute leukaemia, flow cytometry, protein phosphorylation,
prognostic factors, molecular diagnostics.
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identifying AML with an unfavourable outcome (Min et al,
2003). In the light of these findings, it would seem important
to routinely analyse Akt activity in patients with AML.
Analysis of Akt activity relies on the use of the Akt kinase
assay or Western blot analysis with phosphorylation-specific
antibodies (e.g. Brognard et al, 2001). However, both of these
techniques are time-consuming and require a substantial
number of cells, which might not be available in some AML
cases. Conversely, flow cytometry is a technique that is faster to
perform and requires lower number of cells in comparison
with Western blotting. Moreover, flow cytometric analysis of
AML cells stained for cytoplasmic antigens is now well-
standardized and routinely performed (Curti et al, 2001,
2002). In particular, oncogene products and cell cycle-related
proteins can be analysed and quantified (Bradbury et al, 1997;
Keng & Siemann, 1998; Kusenda, 1998; Milosevic, 2000), and
different approaches (e.g. analysis of phosphorylated compo-
nents, double staining with surface markers and distribution of
the antigen along the cell cycle by contemporary staining with
propidium iodide) might be devised.
This study was designed in order to ascertain whether flow
cytometry could be used to detect Ser 473 phosphorylation in
AML blasts rather than the more traditional time-consuming




Peripheral blood samples from patients presenting with AML
were obtained at diagnosis and separated by Ficoll/Histopaque
gradient centrifugation. Informed consent was obtained in
accordance with institutional guidelines. The AML cases were
defined according to the French-American-British (FAB)
classification. The percentage of blasts in the samples always
exceeded 90% and was checked by flow cytometry staining,
depending on the phenotype of the leukaemia (usually CD13,
CD33, CD34, alone or in combination).
Cord blood (CB) and granulocytes samples were also
collected according to institutional guidelines, following
standard techniques (e.g. Hsu et al, 2002; Secchiero et al,
2004). The purity of CD34-selected cells from CB was
determined by flow cytometry using a phycoerythrin (PE)-
conjugated monoclonal antibody, which recognizes a separate
epitope of the CD34 molecule (581, Beckman Coulter, Miami,
FL, USA). The purity of CD34+ preparations ranged between
93% and 98%.
Tissue culture
Human Jurkat T cells were cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS) in 5% CO2 and 95% air at
37C, at an optimal cell density of 3–8 · 105 cells/ml.
Preparations of cell homogenates for Western blot analysis
Cells (at least 2 · 106/sample) were resuspended at 107/ml in
10 mmol/l Tris-HCl, pH 7Æ4, 1 mmol/l MgCl2, 1 mmol/l
ethyleneglycotetraacetic acid (EGTA), 1% Triton X-100,
250 mmol/l sucrose, 25 mmol/l NaPPi, supplemented with
the COMPLETE Protease Inhibitor Cocktail (Roche Molecular
Biochemicals, Milan, Italy). Samples were incubated at 4C for
15 min, then centrifuged at 10 000 g for 10 min at 4C.
Protein concentration was assayed using the Protein Assay kit
(detergent compatible, from Bio-Rad, Hercules, CA, USA).
Lysates were stored at )80C until required.
Western blot analysis
Protein (80 lg/sample), separated on sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE), was trans-
ferred to nitrocellulose sheets. Sheets were saturated in phos-
phate-buffered saline (PBS, pH 7Æ4) containing 5% normal goat
serum and 4% bovine serum albumin (blocking buffer) for
60 min at 37C, then incubated overnight at 4C in blocking
buffer containing the primary antibodies (all fromCell Signaling
Technology, Beverly, MA, USA) to total Akt (Catalog no. 9272,
rabbit polyclonal), to Thr 308 p-Akt (Catalog no. 9275, rabbit
polyclonal), to Ser 473 p-Akt (Catalog no. 9271, rabbit
polyclonal, specific forWestern blot analysis). After four washes
in PBS containing 0Æ1% Tween 20, they were incubated for
30 min at room temperature with the appropriate peroxidase-
conjugate secondary antibodies (Sigma, St Louis, MO, USA),
diluted 1:5000 in PBS-Tween 20, and washed as described
above. Bands were visualized by the enhanced chemilumines-
cence (ECL) method (Lumi-LightPlus detection kit; Roche
Molecular Biochemicals). To ensure equal loading, blots were
always first probed with a mouse monoclonal antibody to
b-tubulin (Sigma), then stripped and re-probed. Blots shown
are representative of three different experiments. Densitometric
scan of the blots was performed using the gelscan program
Quantity One (1 Bio-Rad, Hercules, CA, USA).
Akt immunoprecipitation and in vitro kinase assay
This was performed on immunoprecipitates obtained from
4 · 106 cells/sample, as previously reported (Martelli et al,
2003; Neri et al, 2003). Radioactivity was determined by
scintillation counting. Background values, obtained by using
samples in which the anti-Akt antibody was replaced by normal
rabbit immunoglobulin IgG, were subtracted from all values.
Intracellular immunostaining and flow cytometric analysis
Cells (approximately 1–2 · 105/sample) were fixed with rea-
gent 1 of the Intraprep kit, according to the manufacturer’s
instructions (2 Beckman Coulter, Miami, FL, USA). Cells
were then permeabilized with saponin-based reagent 2 and
incubated at 4C for 12 h with a 1:10 final dilution of antibody
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to Ser 473 p-Akt [Cell Signaling Technology; Catalogue no.
9277, specific for immunocytochemistry (ICC)]. Samples were
washed twice with PBS and pellets were incubated with 5 ll
fluorescein isothiocyanate (FITC)-conjugated swine antirabbit
IgG (DakoCytomation, Glostrup, Denmark). Negative controls
were run with FITC-conjugated swine antirabbit IgG alone and
with FITC-conjugated swine antirabbit IgG plus normal rabbit
IgG (Sigma). All the samples were analysed by EPICS XL and
Cytomics FC 500 flow cytometers (Beckman Coulter)
equipped with dedicated software. Histograms were then
analysed with expo software. The fluorescence intensity of
samples stained for Ser 473 p-Akt was calculated by flow
cytometry-dedicated software as mean channel value of
fluorescence (MCV). A double immunostaining procedure
combining surface staining with PE-conjugated anti-CD33
(Beckman Coulter) and cytoplasmic staining for Ser 473 p-Akt
was performed. Briefly, 5 · 105 AML blast cells were incubated
with 10 ll of PE-conjugated anti-CD33 for 20 min at room
temperature. Cells were washed with PBS and then fixed and
stained for Ser 473 p-Akt as described above. The analysis
programme was modified accordingly for acquiring double-
stained events. Control samples were run with the appropriate
FITC- and PE-conjugated negative controls.
To analyse the effect of sample cryopreservation on the
amount of Ser 473 p-Akt, freshly isolated blasts from three
AML patients (cases 13–15) were stained as described above.
Aliquots of leukaemic cells of these patients were resuspended
in RPMI 1640 medium containing 20% FBS and 10%
dimethylsulphoxide (DMSO), and cryopreserved in a pro-
grammable freezer according to an electronically monitored
programme at a freeze rate of )1C/min to )120C. The cells,
maintained in the vapour-phase of liquid N2, were thawed at
37C after 7 d, stained, and analysed by flow cytometry and
Western blot for Ser 473 p-Akt.
Results
Patients
The blasts from 15 patients diagnosed with AML were
employed in this study. The FAB classification and karyotype
analysis of these AMLs are reported in Table I.
Western blot analysis
Total Akt, Thr 308 p-Akt and Ser473 p-Akt expression relative
to b-tubulin levels was determined by Western blot analysis.
Controls included the Jurkat cell line with constitutive
activation of Akt (Freeburn et al, 2002) and CB CD34+ cells
and granulocytes with extremely low or undetectable amounts
levels of p-Akt (Majka et al, 2002; Crossley, 2003; Xu et al,
2003). All cells expressed Akt whereas Thr 308 p-Akt and Ser
473 p-Akt were expressed by the Jurkat cells but not CB CD34+
cells and granulocytes. Patients 1–10 expressed both Thr 308
p-Akt and Ser473 p-Akt while levels were reduced in patients
11 and 12 (Fig 1A).
Table I. Characteristics of acute myeliod leukaemia (AML) patients.
Patient FAB classification Karyotype
1 M1 11q23 complex
2, 3 M4 46xy, inv(3) (q21q26)
4, 6 M1 46xx, inv(3) (q21q26)
5 M0 46xx, t(9,11) (q21q23)
7 M5 46xy, inv(3) (q21q26)
8, 9, 13, 14 M1 Normal
10 M1 +8
11, 12 M1 inv(16)
15 M4 Normal
Fig 1. (A) Western blot analysis for total Akt and its phosphorylated
forms. Western blot analysis was performed using antibodies to total
Akt, Thr 308 p-Akt, Ser 473 p-Akt, and to b-tubulin to verify equal
loading. (B) In vitro Akt kinase assay. Akt was immunoprecipitated
from cell extracts using an antibody to total Akt. The assay was
carried out using histone H2B as the exogenous substrate. Results are
the mean of three different experiments ± SD. Note that acute
myeloid leukaemia (AML) blasts from cases 1–12 had been stored in
liquid N2.
Flow Cytometric Detection of p-Akt in AML Blasts
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Akt activity analysis
The phosphorylation of residues Thr 308 and Ser 473 is
required for Akt kinase activation. Measurement of Akt kinase
activity showed reduced activity in granulocytes and CD34+
cells and increased activity in Jurkat cells. Increased activity
was found for patients 1–10 with decreased activities for
patients 11 and 12. Reduced phosphorylation, as shown by
Western blot analysis, confirmed these findings (Fig 1B).
Flow cytometric analysis
Flow cytometric analysis demonstrated the presence of Ser 473
p-Akt in Jurkat cells and the absence of Ser 473 phosphory-
lation in the granulocytes and CD34+ cells (Fig 2). To
determine whether a double staining method could be applied
to AML blasts, the cells were first stained with PE-conjugated
anti-CD33 (CD33-PE) and subsequently, after fixation and
permeabilization, stained with anti-Ser 473 p-Akt antibody
(FITC Ser 473 p-Akt). Patients 1, 2 and 4 showed double
staining of CD33 and cytoplasmic Ser 473 p-Akt (Fig 2). For
all patients, flow cytometric results correlated with Western
blot analysis, with positive results for patients 1–10 while no
signal was observed for patients 11 and 12 (compare Fig 3 with
Fig 1A,B). Interestingly, case 4 had two blast populations, with
different amounts of Ser 473 p-Akt (Fig 3).
The effect of cryopreservation on Ser 473 p-Akt was
determined by staining three AML samples from patients 13,
14 and 15 prior to and following cryopreservation. As shown
in Fig 4, cryopreservation did not affect the results of the
Western blot or flow cytometry analysis.
Comparison of Western blot and flow cytometry analysis
To conclusively demonstrate that the expression of Ser 473
p-Akt detected by Western blot and flow cytometry analysis is
similar, densitometric analysis of Western blots was compared
with the mean fluorescence intensity recorded by flow
cytometry. Although direct correlations could not be made,
relative levels of expression could be compared. Both tech-
niques showed that patient 4 had the highest expression of Ser
473 p-Akt; lower levels of expression were found in patients 1,
2 and 3 (Table II).
Discussion
Recent findings have demonstrated that p-Akt levels could be








Fig 2. Flow cytometric analysis for Ser 473 p-Akt in Jurkat cells (grey
histogram: negative control; black histogram: anti-Ser 473 p-Akt),
granulocytes, CB CD34+ cells and acute myeloid leukaemia (AML)
blasts. Negative controls (CTR) were run with fluorescein isothiocya-
nate (FITC)-conjugated swine antirabbit immunoglobulin IgG plus
normal rabbit IgG. Double immunostaining analysis (surface CD33
versus cytoplasmic Ser 473 p-Akt) was performed on blasts from
patients 1, 2 and 4. Each histogram is representative of three different
experiments.
Fig 3. Flow cytometric analysis for Ser 473 p-Akt in acute myeloid
leukaemia (AML) blasts from 12 patients. Grey histograms: negative
control; black histograms: anti-Ser 473 p-Akt. The results shown are
representative of three different experiments.
P. L. Tazzari et al
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neoplasia, including ovarian cancer, endometrial cancer,
thyroid carcinoma, multiple myeloma and renal carcinoma
(Yuan et al, 2000; Hsu et al, 2001; Kanamori et al, 2001; Ringel
et al, 2001; Horiguchi et al, 2003). Thus, there is a need for
tests that can rapidly evaluate the amount of p-Akt in
pathological specimens, and its eventual response to selective
pharmacological inhibitors. To date, the presence of p-Akt has
mainly been studied by measurement of Akt kinase activity or
Western blot. Although well-standardized, these methods are
time-consuming, require a sizable amount of cells, and cannot
show the different cell subsets with different p-Akt levels that
might be present in human cancers. Immunohistochemical
analysis has been successfully employed for the detection of
p-Akt in human cancer (Horiguchi et al, 2003). However, this
type of technique may be more appropriate for solid tumors.
Flow cytometric analysis might be the best choice for
detecting Ser 473 p-Akt in AML patients, because it can be
performed quickly and requires a limited amount of cells that
are easily collected from the blood or bone marrow. Therefore,
we investigated the possibility of detecting Ser 473 p-Akt by
flow cytometry in AML blasts. For this purpose, we used an
antibody to Ser 473 p-Akt, specific for ICC. The results
obtained by means of flow cytometry analysis were similar to
findings provided by in vitro Akt kinase assay or Western blot
analysis. Regarding the number of cells which are required, it
should be emphasized that, according to our experience,
flow cytometric analysis could be easily performed with
1–2 · 105 cells/sample (although double immunostaining
required 5 · 105 cells/sample), whereas Western blot needed
at least 2 · 106 cells/sample and the in vitro activity assay at
least 4 · 106 cells/sample. Clearly, such a difference in the
required cell number is an important factor that may make
flow cytometry preferable to either Akt kinase activity or
Western blot analysis. We also demonstrated that cryopreser-
vation did not affect the amount of Ser 473 p-Akt of AML
blasts, as detected by Western blot. Similar results for Western
blot analysis have also been reported recently (Xu et al, 2003).
Furthermore, our investigation has shown that cryopreserva-
tion did not influence the data provided by flow cytometric
analysis for Ser 473 p-Akt. Therefore, it would be feasible to
perform retrospective studies using flow cytometry. It will be
also possible to analyse samples obtained from the same
patient at different times, to study the natural history of
remission, minimal residual disease or relapse. Another
advantage offered by flow cytometric analysis is represented
by the possibility of sorting predefined cell populations with
high levels of Ser 473 p-Akt to perform drug sensitivity tests
in vitro, because blasts with high levels of active Akt are most
probably resistant to standard therapeutic treatments.
Moreover, the feasibility of the double immunostaining flow
cytometric procedure for surface and intracytoplasmic anti-
gens makes it possible to characterize AML cases with a low
Fig 4. Effects of cryopreservation on the levels
of Ser 473 p-Akt of acute myeloid leukaemia
(AML) blasts. Flow cytometric analysis and
Western blotting were performed both on
freshly isolated blasts and on cells stored for
1 week in liquid N2. F, freshly isolated; S, stored
in liquid N2. The results shown are representa-
tive of three different experiments. For the other
details see Figs 1 and 3 legends.
Table II. Comparison of densitometric scanning of Ser 473 p-Akt
blots and fluorescence intensity of samples stained for Ser 473 p-Akt,
expressed as mean channel value (MCV).
Case number Densitometric scanning MCV
1 46 ± 6 4Æ48 ± 0Æ48
2 52 ± 6 6Æ40 ± 0Æ71
3 65 ± 8 10Æ24 ± 1Æ19
4 100 ± 11 16Æ6 ± 1Æ79
5 87 ± 9 12Æ80 ± 1Æ34
In both cases, results were originally expressed as arbitrary units. The
patient with the highest values (patient 4) was used to represent 100%.
Data are the mean of three different experiments ± SD.
Flow Cytometric Detection of p-Akt in AML Blasts
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percentage of blastic cells, by utilizing the appropriate CD
antigens for surface staining.
Western blot analysis revealed the phosphorylation of both
Thr 308 and Ser 473 p-Akt in all patients evaluated, which
confirms the findings of Min et al (2003) where both residues
were phosphorylated in 87Æ8% of the patients evaluated
(n ¼ 61). In conclusion, our results show that a quick and
quantitative assessment of Ser 473 p-Akt is possible in human
AML blasts by means of flow cytometry. AMLs are usually
subjected to an extensive phenotyping by flow cytometry to
define their degree of differentiation and, consequently, their
prognosis.
The importance of the phosphoinositide 3-kinase/Akt
pathway is being increasingly recognized in determining
AML resistance to chemotherapeutic treatment (Martelli et al,
2003; Neri et al, 2003; Zhao et al, 2004). Flow cytometric
detection of the p-Akt form could be a useful additional
marker for the prognosis of AML and also aid the development
of better therapeutic approaches to this disease.
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